Calyxt : Investor Presentation

Q2 2021 Investor Presentation

Forward Looking Statements

We have made these forward-looking statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "anticipates," "believes," "continue," "estimates," "expects," "targets," "intends," "may," "might," "plans," "potential," "predicts," "projects," "should," "will," or the negative of these terms and other similar terminology. Forward-looking statements in this report include statements about the potential impact of the COVID-19 pandemic on our business and operating results; our future financial performance; product pipeline and development; our business model and principal strategy for commercialization and sales of commercial products; regulatory progression; potential collaborations, partnerships and licensing arrangements and their contribution to our financial results, cash usage, and growth strategies; and anticipated trends in our business. These and other forward-looking statements are predictions and projections about future events and trends based on our current expectations, objectives and intentions and premised on current assumptions. Our actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; the impact of increased competition; disruptions at our key facilities; changes in customer preferences and market acceptance of our products; competition for collaboration partners and licensees and the successful execution of collaborations and licensing agreements; the impact of adverse events during development, including unsuccessful field trials or developments trials or disruptions in seed production; the impact of improper handling of our product candidates by unaffiliated third parties during development, such as the improper aerial spraying of our high fiber wheat product candidate; failures by third-party contractors; inaccurate demand forecasting; the effectiveness of commercialization efforts by commercial partners or licensees; our ability to make grain sales on terms acceptable to us; the timing of our grain sales; our ability to collect accounts receivable; disruptions to supply chains, including transportation and storage functions; commodity price conditions; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; management changes; dislocations in the capital markets; and other important factors discussed in Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K, which should be considered an integral part of Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations."

Any forward-looking statement made by us is based only on information currently available to us when, and speaks only as of the date, such statement is made. Except as otherwise required by securities and other applicable law, we do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change.

© CAL Y X T , I NC . AL L RI GHT S RE S E RVE D

2

Q1 2021 & Subsequent Key Highlights

• Sarah Reiter promoted to Chief Business Officer
• Early-StageValidation that Next Generation Premium Soybean Product is Best-in-Classfor High Oleic, Ultra-Low
  Linolenic Profile
• Successful Transformation of Hemp Genome Enables Acceleration of Calyxt's Innovation Approaches in the Species
• Execution of New Agreement for Sale of High Oleic
  Soybean Seed
• Completed Sale of More Than 50 Percent of 2020 Grain
  Crop
• Yves Ribeill, Ph.D. named Executive Chair
• Scientific Advisory Board (SAB) formed to focus on identification of high value targets for development and

commercialization	© CAL Y X T , I NC . AL L RI GHT S RE S E RVE D	3

The Ideation that TALEN Could Support

P L A N T - B A S ED S OLU T I ON S

	Plant-Based	Plant-Based
Functional	Protein	Green
Packaging
	Building
Nutrition
		Materials

Advanced

Therapeutics

Regenerative

Agriculture

Animal

Nutrition

Renewable

Clean Energy

© CAL Y X T , I NC . AL L RI GHT S RE S E RVE D

4

Development Process

P O W E R E D B Y :

1-2 years

1-2 years

1-2 years

1-2 years

1-2 years

Imagine

We or our partners imagine the

possibilities for a product

concept.

Discover & Target	Develop & Validate	Breed & Field Test	Confirm & Consult	Grow & Process
We discover biochemical	Using our technologies, we	We use germplasm	We work with our partners to	Our partner(s) commercially
pathways and traits of	edit selected target genes.	acquisition, trait integration,	confirm trait performance	plant the seed and harvest
underlying genes. We then	We then validate the seeds	seed increase, and field	and complete any final	the grain, which includes our
target traits in those specific	by genotyping for product	testing to validate product	regulatory consultations or	trait.
genes using our	candidate selection.	quality.	necessary approvals.
technologies like TALEN®.